Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
Launched by ABBVIE · Apr 26, 2021
Trial Information
Current as of August 31, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the safety and effects of a medicine called risankizumab in children and teenagers (ages 6 to 17) who have moderate to severe plaque psoriasis, a skin condition that causes thick, red, and scaly patches. The study focuses on participants who have already finished an earlier risankizumab study (called M19-977) to see how their disease changes and if they experience any side effects while continuing treatment.
To join the trial, participants must have completed the previous study and meet certain health criteria. During the study, they will receive injections of risankizumab under the skin every 12 weeks for almost four years. They will also have regular visits to the clinic or hospital for check-ups, blood tests, and to talk about any side effects or changes in their condition. Because of these visits and treatments, the study might require more time and effort than their usual care. The main goal is to understand how safe and effective risankizumab is for young people with this skin condition over a long period.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • --Participants who have completed participation in study M19-977 and who meet all eligibility criteria for participation in Study M19-973 will be allowed to enroll in study M19-973.
- Exclusion Criteria:
- • --Participants who have developed any discontinuation criteria as defined in Study M19-977.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fountain Valley, California, United States
Sacramento, California, United States
Jacksonville, Florida, United States
Largo, Florida, United States
Darien, Illinois, United States
Rolling Meadows, Illinois, United States
Muenster, Nordrhein Westfalen, Germany
Kiel, Schleswig Holstein, Germany
Bad Bentheim, , Germany
Bonn, , Germany
Dresden, , Germany
Mainz, , Germany
Lodz, Lodzkie, Poland
Rzeszow, Podkarpackie, Poland
Gdansk, Pomorskie, Poland
Esplugues De Llobregat, Barcelona, Spain
Madrid, , Spain
Madrid, , Spain
Madrid, , Spain
Pontevedra, , Spain
Saint Petersburg, Florida, United States
Tampa, Florida, United States
Reno, Nevada, United States
Cleveland, Ohio, United States
Mayfield Heights, Ohio, United States
Charleston, South Carolina, United States
Calgary, Alberta, Canada
St. John's, Newfoundland And Labrador, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Nagoya Shi, Aichi, Japan
Lodz, Lodzkie, Poland
Warszawa, Mazowieckie, Poland
Exeter, Devon, United Kingdom
London, London, City Of, United Kingdom
Camberley, , United Kingdom
London, , United Kingdom
Plymouth, , United Kingdom
Exeter, Devon, United Kingdom
London, , United Kingdom
Exeter, Devon, United Kingdom
Birmingham, Alabama, United States
Fountain Valley, California, United States
Sacramento, California, United States
San Diego, California, United States
Tampa, Florida, United States
Reno, Nevada, United States
Mayfield Heights, Ohio, United States
Bonn, Nordrhein Westfalen, Germany
Mainz, Rheinland Pfalz, Germany
Tsu, Mie, Japan
Hirakata Shi, Osaka, Japan
Shinjuku Ku, Tokyo, Japan
Rzeszow, Podkarpackie, Poland
Exeter, Devon, United Kingdom
Plymouth, Devon, United Kingdom
London, , United Kingdom
Morgantown, West Virginia, United States
Milwaukee, Wisconsin, United States
Bad Bentheim, Niedersachsen, Germany
Dresden, Sachsen, Germany
Hirakata Shi, Osaka, Japan
London, Greater London, United Kingdom
London, Greater London, United Kingdom
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials